drugset
drugset / Trial / NCT05335044

Study to Evaluate the Safety and Pharmacokinetics of CKD-331

NCT05335044 ↗

Phase 1 Completed 47 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

Phase 1 study to evaluate the safety and pharmacokinetics of CKD-331 in healthy adult volunteers

Timeline

Start
2022-05-31
Primary completion
2022-06-23
Completion
2022-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-331 Unknown — Oral
Subject EX5619 Unknown — Oral

Indications

No indication recorded.